Innovent Biologics, IASO Bio strengthen collaboration with equity investment and licensing deal
Innovent Biologics, Inc. (HKEX: 01801), a globally recognized biopharmaceutical company, and IASO Biotechnology, a leader in innovative cell therapies and antibody products, have announced a ... Read More
Poseida Therapeutics gets FDA orphan drug designation for P-BCMA-ALLO1 in multiple myeloma
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a trailblazer in the field of clinical-stage cell and gene therapy, has achieved a significant milestone with the U.S. Food ... Read More
Thermo Fisher Scientific and JW Therapeutics forge strategic CAR-T therapy partnership in China
Thermo Fisher Scientific has entered into a significant agreement with Chinese cell therapy leader JW Therapeutics, granting non-exclusive commercial access to its Gibco CTS Dynabeads ... Read More
Novartis aims to strengthen cell therapy capabilities with CellforCure acquisition
Novartis has announced plans to acquire CellforCure, a French contract development and manufacturing organisation (CDMO), from LFB for an undisclosed amount. The deal underscores the ... Read More
Novartis completes $2.1bn acquisition of Endocyte to boost cancer treatment capabilities
Swiss pharmaceutical giant Novartis has officially closed its $2.1 billion acquisition of US-based biopharma company Endocyte, solidifying its position as a leader in radiopharmaceuticals for ... Read More
FDA grants approval to Yescarta for treatment of certain types of lymphoma
In a significant development for lymphoma treatment, Kite Pharma, a subsidiary of Gilead Sciences, has received approval from the U.S. Food and Drug Administration (FDA) ... Read More
FDA clears Servier and Pfizer for clinical development of UCART19 for acute lymphoblastic leukemia
Servier and Pfizer Inc. have received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to proceed with the clinical development ... Read More